Dimension Therapeutics Inc. (NASDAQ:DMTX) was up 9.8% on Wednesday . The company traded as high as $7.47 and last traded at $7.39, with a volume of 57,199 shares changing hands. The stock had previously closed at $6.73.

A number of equities research analysts have weighed in on DMTX shares. Cantor Fitzgerald reissued a “buy” rating on shares of Dimension Therapeutics in a report on Wednesday, June 22nd. Zacks Investment Research downgraded shares of Dimension Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, April 14th. Citigroup Inc. cut their price objective on Dimension Therapeutics from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Tuesday, March 29th. Goldman Sachs Group Inc. downgraded Dimension Therapeutics from a “buy” rating to a “neutral” rating and set a $10.00 price objective on the stock. in a report on Wednesday, March 30th. Finally, Chardan Capital restated a “hold” rating on shares of Dimension Therapeutics in a report on Tuesday, March 29th. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $17.56.

The firm’s market cap is $184.91 million. The firm’s 50-day moving average price is $7.56 and its 200 day moving average price is $7.64.

Dimension Therapeutics (NASDAQ:DMTX) last announced its earnings results on Thursday, May 12th. The company reported ($0.38) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.57) by $0.19. The business earned $2.21 million during the quarter, compared to analyst estimates of $2.24 million. Analysts forecast that Dimension Therapeutics Inc. will post ($1.96) earnings per share for the current fiscal year.

In other news, SVP K. Reed Clark sold 5,000 shares of the firm’s stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $10.00, for a total value of $50,000.00. Following the completion of the sale, the senior vice president now directly owns 5,000 shares in the company, valued at $50,000. The sale was disclosed in a filing with the SEC, which is accessible through this link.

An institutional investor recently bought a new position in Dimension Therapeutics stock. Jennison Associates LLC acquired a new position in Dimension Therapeutics Inc. (NASDAQ:DMTX) during the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 742,454 shares of the company’s stock, valued at approximately $8,265,000. Jennison Associates LLC owned 2.97% of Dimension Therapeutics at the end of the most recent quarter.

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.